With Proleukin, you can offer an immunotherapy that has been proven to provide over 10 years of durable complete responses in patients with metastatic renal cell carcinoma (mRCC) or metastatic melanoma (mM).1-3
Complete response rates achieved were 7% in mRCC patients and 6% in mM patients.1-3
≥ 90% of IL-2 responders achieved a response after their first course of Proleukin.4,*
Responses may be evident as early as 4 weeks after treatment.1,4
Proleukin does not limit the use of additional cancer therapies, which have been proven to be effective after cytokine treatment.5
You and your patients do not have to wait long for your assessment: may begin as early as 4 weeks after treatment.1
Proleukin is supported by over 20 years of real-world clinical experience at specialized IL-2 Treatment Centers.1,6
*Treatment with Proleukin is typically based on two 5-day cycles that constitute 1 course of therapy, with 9 days of rest in between. Patients who respond to Proleukin can go on to receive additional courses, while nonresponders are typically eligible for other treatment options.1
Are your patients ECOG Performance Status 1 or 0?
Proleukin may be an ideal option for ECOG Performance Status 1 or 0 patients who are candidates for treatment.7,8
Providing hope is possible with Proleukin.1-3
Complete response rates were 7% in mRCC patients and 6% in mM patients.1-3
Myths and facts about Proleukin
Myth: Proleukin is only for younger patients.
Fact: Both younger and older patients who are ECOG Performance Status 1 or 0—and are otherwise healthy—may be candidates for Proleukin.7,8
Myth: Treatment-related side effects are unmanageable.
Fact: Under the care of highly trained clinicians at expert Treatment Centers, treatment-related side effects can be managed. Most improve within 2 to 3 days of discontinuing therapy.1,7,8
Myth: Long-term side effects are common.
Fact: Long-term sequelae associated with Proleukin are extremely rare, but may include myocardial infarction, bowel perforation, and gangrene.8
Myth: I’ll lose track of my patients at the IL-2 Treatment Center.
Fact: You can keep track of patients during their treatment at the expert IL-2 Treatment Center. Keeping an open line of communication is important.
References: 1. Proleukin [package insert]. Yardley, PA: Clinigen, Inc; 2019. 2. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1):S55-S57. 3. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11-S14. 4. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol. 2000;18(9):1954-1959. 5. Sutent [package insert]. New York, NY: Pfizer Inc; 2017. 6. Dutcher JP, Schwartzentruber DJ, Kaufman HL, et al. High dose interleukin-2 (aldesleukin)—expert consensus on best management practices—2014. J Immunother Cancer. 2014;2(1):26. 7. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688-696. 8. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17(7):2105-2116.